In this briefing:
- The Economic and Financial Implications of Closing the Gilded Age for US Technology Companies
- Global Tech Breakup
- Dongzheng Auto Finance (东正汽车金融) IPO Review – Better off Buying the Parent
- CanSino Biologics (康希诺) IPO: Valuation Update (Part 3)
- Momo (MOMO): Paying Users Up 17%, Benefiting from Bankrupt Competitors, 80% Upside
1. The Economic and Financial Implications of Closing the Gilded Age for US Technology Companies
The technology sector’s influence on the US economy and financial markets over the past two decades has been significant, and largely considered to be beneficial, but these legacies may now be under threat from political and consumer backlashes.
Motivations for regulating large technology companies vary on a cross-border basis, ranging from customer data protection in the European Union (EU) to antitrust issues in the US.
Imposing utility-type regulations on technology companies that limit investment returns will hinder technological innovation, and, consequently, be detrimental to GDP growth for countries with ageing populations.
Digital technology innovation has produced permanent labour-saving investment opportunities in the US that have hollowed out job openings, thereby contributing to a flatter Phillips Curve and populism.
Meanwhile, populism and technological disputes are also evident on a cross-border basis, as testified by the current Sino-US trade standoff and leadership rivalry in 5G technology.
US political intervention after the 2020 Presidential Election could have a major bearing on market structures and capital destruction within the technology sector, particularly if antitrust measures gain bipartisan support.
2. Global Tech Breakup
By Eleanor Olcott, China Policy Analyst at TS Lombard
- Washington’s political drive to block Chinese access to US high-end tech is creating uncertainty in the industry
- The immediate effect is the redirection of Chinese VC money away from the US to Asian and European rivals
- The long-term trend is of two rival centres of technology production- one focused on Shenzhen, the other on Silicon Valley
3. Dongzheng Auto Finance (东正汽车金融) IPO Review – Better off Buying the Parent
Dongzheng Automotive Finance (2718 HK) is raising up to US$428m in its upcoming IPO. We have covered the background of the company in Dongzheng Auto Finance (东正汽车金融) Pre-IPO Review – Dependent on Dealership Network for Growth.
In this insight, we will look into the company’s valuation, compare it to listed auto peers, and run the deal through our framework.
4. CanSino Biologics (康希诺) IPO: Valuation Update (Part 3)
CanSino is a China-based biotechnology company with a focus on vaccine development. In our previous insight (link to Part 1 and Part 2), we have discussed CanSino’s drug pipeline, the competitive landscape, and the valuation.
As the company is starting pre-marketing, we will provide an updated valuation based on new information obtained from the approved application document. Our base case valuation for CanSino is USD 856 million on a pre-money basis. Majority of the rNPV based SOTP valuation still comes from its meningococcal conjugate vaccine (MCV2 and MCV4). Over the past few months, the company has completed Phase III for MCV4 and submitted NDA (new drug application) for MCV2 candidates.
5. Momo (MOMO): Paying Users Up 17%, Benefiting from Bankrupt Competitors, 80% Upside
- The stock price has risen 32% after the short seller J Capital slammed it.
- MOMO’s paying user base of live video increased 22% yoy in 3Q18 and 17% yoy in 4Q2018 even though the live show market shrank in 2018.
- We believe MOMO will benefit from small competitors’ bankruptcy.
- The growth rate of the main business revenues stopped declining.
- Our P/E band suggests upside of 80% for MOMO’s stock price.
Get Straight to the Source on Smartkarma
Smartkarma supports the world’s leading investors with high-quality, timely, and actionable Insights. Subscribe now for unlimited access, or request a demo below.